Clinical trialNCT01187108CompletedPhase 1/PHASE2Interventional

Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru

SponsorUniversity of Colorado, DenverEnrollment85ErythrocytosisMountain Sickness

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Chronic mountain sickness is characterized by excessive red blood cell production which causes sludging of the vascular system. This high viscosity blood causes heart failure, cognitive dysfunction, and strokes. The investigators hypothesize that cobalt which has been previously been shown to be an environmental pollutant worsens the overproduction of red blood cells. The investigators plan to conduct a 6 week trial in which acetazolamide (already shown to improve chronic mountain sickness) and N-acetylcysteine (a drug that removes cobalt from the blood) are evaluated in their potential to improve chronic mountain sickness.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Abdias Hurtado, MD
Universidad Peruana Cayetano Heredia
Principal Investigator
clinicaltrials.gov ↗
Richard Fuquay, MD
University of Colorado Denver Health Sciences Center
Study Director
clinicaltrials.gov ↗
Richard Johnson, MD
University of Colorado Denver Health Sciences Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Peru

Chronic Mountain Sickness Clinic
Cerro de Pasco, Departamento de Pasco, Peru

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Acetazolamide →Acetylcysteine →Placebo pills

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2013
Primary completion: 30 Sept 2013
Completion: 30 Sept 2013
Last update posted: 15 May 2015
Registered enrollment: 85
Registry id: NCT01187108

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.